Contineum Therapeutics (CTNM) Expected to Post Quarterly Earnings on Thursday

Contineum Therapeutics (NASDAQ:CTNM) is expected to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of ($0.45) per share and revenue of $5.65 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.

Contineum Therapeutics (NASDAQ:CTNM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.05. On average, analysts expect Contineum Therapeutics to post ($1.68) EPS for the current fiscal year and ($1.64) EPS for the next fiscal year.

Contineum Therapeutics Stock Performance

Shares of Contineum Therapeutics stock opened at $8.14 on Tuesday. Contineum Therapeutics has a 52 week low of $6.72 and a 52 week high of $17.78. The stock has a 50 day moving average price of $13.31 and a two-hundred day moving average price of $13.54. The stock has a market capitalization of $306.23 million, a PE ratio of -4.71 and a beta of 0.86.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CTNM. Robert W. Baird cut Contineum Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $19.00 to $14.00 in a report on Tuesday, October 13th. Wall Street Zen cut shares of Contineum Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Morgan Stanley decreased their target price on shares of Contineum Therapeutics from $18.00 to $17.00 and set an “equal weight” rating for the company in a research report on Monday, September 28th. Royal Bank Of Canada upped their target price on shares of Contineum Therapeutics from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Stifel Nicolaus set a $28.00 price target on shares of Contineum Therapeutics in a research report on Wednesday, September 30th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Contineum Therapeutics has an average rating of “Hold” and a consensus target price of $22.33.

About Contineum Therapeutics

Contineum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological and neuroinflammatory diseases. The company’s research is centered on restoring nervous-system function and addressing conditions in which inflammation or damage to myelin contributes to disease progression.

Contineum’s lead programs include PIPE-307, an oral, selective M1 muscarinic receptor antagonist being studied for its potential to promote remyelination in multiple sclerosis, and PIPE-791, an oral, central nervous system-penetrant LPA1 antagonist being developed for progressive multiple sclerosis and other fibrotic or neuroinflammatory conditions.